Kiley Juergens Wealth Management LLC Makes New $1.25 Million Investment in Amgen Inc. $AMGN

Posted by Stanley Muller on Jul 7th, 2026

Kiley Juergens Wealth Management LLC purchased a new stake in Amgen Inc. (NASDAQ:AMGN – Free Report) in the first quarter, Holdings Channel reports. The firm purchased 3,566 shares of the medical research company’s stock, valued at approximately $1,255,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Dogwood Wealth Management LLC grew its holdings in Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after buying an additional 55 shares in the last quarter. Anfield Capital Management LLC boosted its position in shares of Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 70 shares during the last quarter. Board of the Pension Protection Fund acquired a new position in shares of Amgen during the 4th quarter valued at about $26,000. Tower View Wealth Management LLC grew its holdings in shares of Amgen by 331.6% in the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 63 shares during the period. Finally, Manning & Napier Advisors LLC grew its holdings in shares of Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 32 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on AMGN. Wells Fargo & Company lifted their target price on shares of Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a research note on Thursday, March 19th. Royal Bank Of Canada restated a “positive” rating on shares of Amgen in a report on Thursday, June 18th. Canaccord Genuity Group began coverage on Amgen in a report on Monday, April 20th. They issued a “hold” rating and a $366.00 price objective on the stock. Argus cut their target price on Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research note on Wednesday, May 20th. Finally, UBS Group raised their target price on Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Amgen currently has a consensus rating of “Hold” and an average target price of $356.00.

Get Our Latest Research Report on AMGN

Insider Transactions at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.85% of the stock is owned by company insiders.

Amgen Trading Up 0.9%

Shares of AMGN traded up $3.35 during midday trading on Tuesday, hitting $369.79. 359,291 shares of the stock were exchanged, compared to its average volume of 2,768,147. Amgen Inc. has a 52-week low of $269.77 and a 52-week high of $391.29. The stock has a fifty day simple moving average of $342.43 and a 200 day simple moving average of $348.09. The firm has a market cap of $199.58 billion, a P/E ratio of 25.72, a P/E/G ratio of 3.68 and a beta of 0.41. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter in the previous year, the business earned $4.90 EPS. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts anticipate that Amgen Inc. will post 22.39 EPS for the current fiscal year.

More Amgen News

Here are the key news stories impacting Amgen this week:

Positive Sentiment: Truist raised its price target on Amgen to $340 from $327, signaling slightly improved expectations even though it kept a hold rating. Benzinga report on Truist target increase
Positive Sentiment: Zacks upgraded Amgen to Buy (Rank #2), citing better earnings outlook, which could support shares in the near term. Yahoo Finance/Zacks upgrade report
Neutral Sentiment: Cantor Fitzgerald reaffirmed its neutral rating and set a $350 target, indicating the stock may be priced a bit ahead of fundamentals. American Banking News Cantor Fitzgerald report
Negative Sentiment: Amgen was also highlighted as trading below market strength in a recent report, reflecting pressure on the shares after a prior decline and ongoing investor caution around Tavneos and pipeline prospects. Yahoo Finance stock dips report
Negative Sentiment: Quiver Quant noted regulatory scrutiny of Tavneos and questions about Amgen’s pipeline, especially in obesity, which has weighed on investor sentiment. Quiver Quant analysis

Amgen Profile

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.